Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Miranda, Enrique ^a,b   Maya Pineda, Hector ^a   Öberg, Daniel ^a,c   Cherubini, Gioia ^a   Garate, Zita ^a   Lemoine, Nick R ^a   Halldén, Gunnel ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; HISTONE ACETYLTRANSFERASE PCAF; MITOXANTRONE; ONCOLYTIC VIRUS; PROTEIN; PROTEIN E1A12S; PROTEIN P21; PROTEIN P400; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KILLING; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; E1ACR1 GENE; EPITHELIUM CELL; GENE; GENE DELETION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; TRANSACTIVATION; TUMOR XENOGRAFT; VIRUS CELL INTERACTION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TYPING;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICE, INBRED C57BL; MITOXANTRONE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 84867049698     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046617     Document Type: Article

References (56)

1. Parato KA, Senger D, Forsyth PA, Bell JC, (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
2. Ekblad M, Hallden G, (2010) Adenovirus-based therapy for prostate cancer. Curr Opin Mol Ther 12: 421-431.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
4. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, et al. (2006) A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
5. Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Bjorklund AC, et al. (2012) Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell death & disease 3: e262.
6. Dutt SS, Gao AC, (2009) Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 5: 1403-1413.
7. Dong JT, (2006) Prevalent mutations in prostate cancer. J Cell Biochem 97: 433-447.
8. Skjoth IH, Issinger OG, (2006) Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 28: 217-229.
9. Freytag SO, Stricker H, Movsas B, Kim JH, (2007) Prostate cancer gene therapy clinical trials. Mol Ther 15: 1042-1052.
10. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, et al. (2007) Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15: 1016-1023.
11. Berk AJ, (2005) Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24: 7673-7685.
12. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, et al. (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6: 611-623.
13. Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, et al. (2007) Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15: 636-642.
14. Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, et al. (2006) Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 13: 347-356.
15. Aghi M, Martuza RL, (2005) Oncolytic viral therapies- the clinical experience. Oncogene 24: 7802-7816.
16. Öberg D, Yanover E, Sweeney K, Adam V, Costas C, et al. (2010) Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant (AdΔΔ) in prostate and pancreatic cancers. Clin Canc Res pp. 541-553.
17. Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, et al. (2009) Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res 15: 5396-5403.
18. de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, (2010) Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy. Hum Gene Ther 21: 795-805.
19. Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, et al. (2010) Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Hum Gene Ther 21: 1311-1325.
20. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, et al. (2005) Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12: 284-294.
21. Debbas M, White E, (1993) Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & development 7: 546-554.
22. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, et al. (1992) The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89: 7742-7746.
23. White E, Cipriani R, Sabbatini P, Denton A, (1991) Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol 65: 2968-2978.
24. Chattopadhyay D, Ghosh MK, Mal A, Harter ML, (2001) Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells. J Virol 75: 9844-9856.
25. Putzer BM, Stiewe T, Parssanedjad K, Rega S, Esche H, (2000) E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death Differ 7: 177-188.
26. Cook JL, Miura TA, Ikle DN, Lewis AM Jr, Routes JM, (2003) E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res 63: 3435-3443.
27. Liao Y, Yu D, Hung MC, (2007) Novel approaches for chemosensitization of breast cancer cells: the E1A story. Adv Exp Med Biol 608: 144-169.
28. Samuelson AV, Narita M, Chan HM, Jin J, de Stanchina E, et al. (2005) p400 is required for E1A to promote apoptosis. J Biol Chem 280: 21915-21923.
29. Samuelson AV, Lowe SW, (1997) Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proc Natl Acad Sci USA 94: 12094-12099.
30. Frisch SM, Mymryk JS, (2002) Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 3: 441-452.
31. Gallimore PH, Turnell AS, (2001) Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 20: 7824-7835.
32. Pelka P, Ablack JN, Torchia J, Turnell AS, Grand RJ, et al. (2009) Transcriptional control by adenovirus E1A conserved region 3 via p300/CBP. Nucleic Acids Res 37: 1095-1106.
33. Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, et al. (2005) Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 12: 1198-1205.
34. Chang CY, Lin YM, Lee WP, Hsu HH, Chen EI, (2006) Involvement of Bcl-X(L) deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells. Oncogene 25: 2656-2665.
35. Jelsma TN, Howe JA, Evelegh CM, Cunniff NF, Skiadopoulos MH, et al. (1988) Use of deletion and point mutants spanning the coding region of the adenovirus 5 E1A gene to define a domain that is essential for transcriptional activation. Virology 163: 494-502.
36. Jelsma TN, Howe JA, Mymryk JS, Evelegh CM, Cunniff NF, et al. (1989) Sequences in E1A proteins of human adenovirus 5 required for cell transformation, repression of a transcriptional enhancer, and induction of proliferating cell nuclear antigen. Virology 171: 120-130.
37. Egan C, Jelsma TN, Howe JA, Bayley ST, Ferguson B, et al. (1988) Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol Cell Biol 8: 3955-3959.
38. Howe JA, Mymryk JS, Egan C, Branton PE, Bayley ST, (1990) Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc Natl Acad Sci USA 87: 5883-5887.
39. Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, et al. (2008) E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 15: 40-50.
40. Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Muller H, et al. (2011) The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene therapy 18: 1157-1165.
41. Fox EJ, (2004) Mechanism of action of mitoxantrone. Neurology 63: S15-18.
42. Fabbri F, Amadori D, Carloni S, Brigliadori G, Tesei A, et al. (2008) Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol 217: 494-501.
43. Loewenstein PM, Arackal S, Green M, (2006) Mutational and functional analysis of an essential subdomain of the adenovirus E1A N-terminal transcription repression domain. Virology 351: 312-321.
44. Loewenstein PM, Wu SY, Chiang CM, Green M, (2012) The adenovirus E1A N-terminal repression domain represses transcription from a chromatin template in vitro. Virology 428: 70-75.
45. Savelyeva I, Dobbelstein M, (2011) Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A. Oncogene 30: 865-875.
46. Lavery DN, Bevan CL, (2011) Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed & Biotech 2011: 862125.
47. Chiou SK, White E, (1997) p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J Virol 71: 3515-3525.
48. Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, et al. (2005) Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7: 723-729.
49. Helgason GV, O'Prey J, Ryan KM, (2010) Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. Cancer Res 70: 4074-4080.
50. Mymryk JS, Shire K, Bayley ST, (1994) Induction of apoptosis by adenovirus type 5 E1A in rat cells requires a proliferation block. Oncogene 9: 1187-1193.
51. Rasti M, Grand RJ, Mymryk JS, Gallimore PH, Turnell AS, (2005) Recruitment of CBP/p300, TATA-binding protein, and S8 to distinct regions at the N terminus of adenovirus E1A. J Virol 79: 5594-5605.
52. White E, (2001) Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 20: 7836-7846.
53. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC, (1995) Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem and Mol Biol 52: 403-413.
54. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
55. Wang Y, Hallden G, Hill R, Anand A, Liu TC, et al. (2003) E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21: 1328-1335.
56. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, et al. (2009) Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 15: 1730-1740.